You are here
The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.
CMEC Meeting 21, 6-7 July 2000
Complementary Medicines Evaluation Committee
Extracted ratified minutes
Public recommendation summary
CMEC endorses the work in progress on the amended document Guidelines for levels and kinds of evidence to support claims for therapeutic goods.
CMEC confirms its previous advice to the TGA that all medicines containing St John's Wort (Hypericum perforatum) and intended for oral use must carry the following label warning:
'St John's Wort affects the way some prescription medicines work. Consult your doctor.'
However CMEC considers that homoeopathic preparations of St John's Wort, other than mother tinctures, should not be required to carry the above warning.
CMEC recommends to the TGA that L-, DL- and D-arginine are not suitable for use as active ingredients in listable therapeutic goods.
CMEC recommends to the TGA that the substance 'tocotrienols complex - palm-derived' is suitable for use as an active ingredient in listable therapeutic goods, without any substance-specific restrictions.
Members endorsed the content of the document Format for draft compositional guidelines for chemical substances and noted that it will be released for stakeholder comment.
CMEC recommends to the TGA that for all homoeopathic medicines, whether registered, listed or exempt from inclusion in the Australian Register of Therapeutic Goods, both the name of the goods and the name of the active ingredients present in them, should be qualified with the prefix 'homoeopathic' to differentiate them from their non-homoeopathic counterparts.
Item 10.9 Colloidal anhydrous silica and silicon dioxide - clarification of the intent of a CMEC recommendation
CMEC recommends to the TGA that the existing restriction on the use of colloidal anhydrous silica and silicon dioxide, that they not be presented in a powdered dosage form when used as active ingredients in listable therapeutic goods, be removed. CMEC further recommends that colloidal anhydrous silica and silicon dioxide should not be permitted for use in listable goods, as either active or excipient ingredients, when the intended route of administration of these goods is by inhalation.
|CMEC 21 Extracted Ratified Minutes (pdf)||126KB|